Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Atherosclerosis Reports
Published in: Current Atherosclerosis Reports 5/2013

Open Access 01-05-2013 | Vascular Biology (RS Rosenson, Section Editor)

Oxidized PLs and Vascular Inflammation

Authors: Maceler Aldrovandi, Valerie B. O’Donnell

Published in: Current Atherosclerosis Reports | Issue 5/2013

Login to get access

Abstract

Oxidized PLs (OxPLs) generated in health and disease are now recognized as important mediators of cellular signalling. There is an increasing body of evidence showing that PL peroxidation is not only increased in vascular disorders, but is also a physiological event of relevance to coagulation, innate immunity, and self-tolerance. Nonenzymatically formed OxPLs generated during chronic inflammation is an uncontrolled event, generating hundreds of diverse structures, and prone to more deleterious bioactivities. In contrast, enzymatic formation of OxPLs is tightly regulated, involving receptors and intracellular signaling, acting as part of the normal physiological response to injury in order to restore homeostasis. In the present review, the major nonenzymatic OxPLs structures found during vascular inflammation are summarized, along with a brief description of their known biological activities. Also, we review what is currently known about enzymatic formation of OxPLs by acutely activated immune cells and their signaling actions under homeostatic and pathological conditions.
Literature
1.
•• Bochkov VN, Oskolkova OV, Birukov KG, et al. Antioxid Redox Signal. 2010;12:1009–59. This review comprehensively summarizes the myriad of known oxidized phospholipid species and their biological actions.PubMedCrossRef
2.
Fruhwirth GO, Loidl A, Hermetter A. Oxidized phospholipids: from molecular properties to disease. Biochim Biophys Acta. 2007;1772(7):718–36.PubMedCrossRef
3.
Morgan AH, Dioszeghy V, Maskrey BH, et al. Phosphatidylethanolamine-esterified eicosanoids in the mouse: tissue localization and inflammation dependent formation in Th-2 disease. J Biol Chem. 2009;284(32):21185–91.PubMedCrossRef
4.
•• Hammond VJ, Morgan AH, Lauder SN, et al. Novel keto-phospholipids are generated by monocytes and macrophages, detected in Cystic Fibrosis, and activate peroxisome proliferator-activated receptor-γ. J Biol Chem. 2012;287(50):41651–66. This study identified the formation of 12-KETE-PEs and 15-KETE-PEs in murine peritoneal macrophages and human monocytes, respectively, which activate PPARγ and may be contribute to the immune regulatory actions of mammalian LOXs in health and disease. PubMedCrossRef
5.
•• Thomas CP, Morgan LT, Maskrey BH, et al. Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation. J Biol Chem. 2010;285(10):6891–903. This study identifies six new lipids generated by human platelets that can promote tissue factor dependent coagulation in vitro. PubMedCrossRef
6.
• Morgan LT, Thomas CP, Kühn H, O'Donnell VB. Thrombin-activated human platelets acutely generate oxidized docosahexaenoic-acid-containing phospholipids via 12-lipoxygenase. Biochem J. 2010;431(1):141–8. This study shows formation of new lipids comprising oxidized docosahexaenoic acid attached to phospholipids by thrombin activated human platelets. PubMedCrossRef
7.
•• Clark SR, Guy CJ, Scurr MJ, et al. Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection. Blood. 2011;117(6):2033–43. This study shows generation of novel esterified eicosanoids generated by human neutrophils in vivo and in vitro. PubMedCrossRef
8.
Subbanagounder G, Leitinger N, Shih PT, et al. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: in vitro and In vivo inhibition by WEB 2086. Circ Res. 1999;85(4):311–8.PubMedCrossRef
9.
Androulakis N, Durand H, Ninio E, Tsoukatos DC. Molecular and mechanistic characterization of platelet-activating factor-like bioactivity produced upon LDL oxidation. J Lipid Res. 2005;46(9):1923–32.PubMedCrossRef
10.
Subbanagounder G, Wong JW, Lee H, et al. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem. 2002;277(9):7271–81.PubMedCrossRef
11.
Leitinger N, Tyner TR, Oslund L, et al. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci U S A. 1999;96(21):12010–5.PubMedCrossRef
12.
Blüml S, Rosc B, Lorincz A, et al. The oxidation state of phospholipids controls the oxidative burst in neutrophil granulocytes. J Immunol. 2008;181(6):4347–53.PubMed
13.
Subbanagounder G, Leitinger N, Schwenke DC, et al. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol. 2000;20:2248–54.PubMedCrossRef
14.
Waddington E, Sienuarine K, Puddey I, Croft K. Identification and quantitation of unique fatty acid oxidation products in human atherosclerotic plaque using high-performance liquid chromatography. Anal Biochem. 2001;292(2):234–44.PubMedCrossRef
15.
Hoff HF, O'Neil J, Wu Z, et al. Phospholipid hydroxyalkenals: biological and chemical properties of specific oxidized lipids present in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2003;23(2):275–82.PubMedCrossRef
16.
Podrez EA, Poliakov E, Shen Z, et al. A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem. 2002;277(41):38517–23.PubMedCrossRef
17.
Watson AD, Leitinger N, Navab M, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem. 1997;272(21):13597–607.PubMedCrossRef
18.
Ravandi A, Babaei S, Leung R, et al. Phospholipids and oxophospholipids in atherosclerotic plaques at different stages of plaque development. Lipids. 2004;39(2):97–109.PubMed
19.
•• O'Donnell VB, Murphy RC. New families of bioactive oxidized phospholipids generated by immune cells: identification and signaling actions. Blood. 2012;120(10):1985–92. This review summarizes the enzymatically formed oxidized phospholipids generated by acutely activated immune cells and it reviews the mass spectrometry methods used for identification of these lipids. PubMedCrossRef
20.
• Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204–12. This review summarizes the involvement of the immune system in atherosclerosis. PubMedCrossRef
21.
Berliner JA, Subbanagounder G, Leitinger N, et al. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med. 2001;11(3–4):142–7.PubMedCrossRef
22.
Reis A, Spickett CM. Chemistry of phospholipid oxidation. Biochim Biophys Acta. 2012;1818(10):2374–87.PubMedCrossRef
23.
Smith WL, Murphy RC. Oxidized lipids formed non-enzymatically by reactive oxygen species. J Biol Chem. 2008;283(23):15513–4.PubMedCrossRef
24.
Winterbourn CC, van den Berg JJ, Roitman E, Kuypers FA. Chlorohydrin formation from unsaturated fatty acids reacted with hypochlorous acid. Arch Biochem Biophys. 1992;296(2):547–55.PubMedCrossRef
25.
Jerlich A, Pitt AR, Schaur RJ, Spickett CM. Pathways of phospholipid oxidation by HOCl in human LDL detected by LC-MS. Free Radic Biol Med. 2000;28(5):673–82.PubMedCrossRef
26.
Morrow JD, Minton TA, Mukundan CR, et al. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes. J Biol Chem. 1994;269(6):4317–26.PubMed
27.
Murphy RC, Johnson KM. Cholesterol, reactive oxygen species, and the formation of biologically active mediators. J Biol Chem. 2008;283(23):15521–5.PubMedCrossRef
28.
Jomova K, Valko M. Advances in metal-induced oxidative stress and human disease. Toxicology. 2011;283(2–3):65–87.PubMedCrossRef
29.
Gargalovic PS, Imura M, Zhang B. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci U S A. 2006;103(34):12741–6.PubMedCrossRef
30.
Hörkkö S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. Clin Invest. 1999;103(1):117–28.CrossRef
31.
Lee H, Shi W, Tontonoz P, et al. Role for peroxisome proliferator-activated receptor alpha in oxidized phospholipid-induced synthesis ofmonocyte chemotactic protein-1 and interleukin-8 by endothelial cells. Circ Res. 2000;87(6):516–21.PubMedCrossRef
32.
Loidl A, Sevcsik E, Riesenhuber G, et al. Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells. J Biol Chem. 2003;278(35):32921–8.PubMedCrossRef
33.
Chatterjee S, Berliner JA, Subbanagounder GG, et al. Identification of a biologically active component in minimally oxidized low density lipoprotein (MM-LDL) responsible for aortic smooth muscle cell proliferation. Glycoconj J. 2004;20(5):331–8.PubMedCrossRef
34.
Bochkov VN, Mechtcheriakova D, Lucerna M, et al. Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK/EGR-1 and Ca(++)/NFAT. Blood. 2002;99(1):199–206.PubMedCrossRef
35.
Subbanagounder G, Deng Y, Borromeo C, et al. Hydroxy alkenal phospholipids regulate inflammatory functions of endothelial cells. Vasc Pharmacol. 2002;38(4):201–9.CrossRef
36.
Moore KP, Darley-Usmar V, Morrow J, Roberts 2nd LJ. Formation of F2-isoprostanes during oxidation of human low-density lipoprotein and plasma by peroxynitrite. Circ Res. 1995;77(2):335–41.PubMedCrossRef
37.
Lynch SM, Morrow JD, Roberts 2nd LJ, Frei B. Formation of non-cyclooxygenase-derived prostanoids (F2-isoprostanes) in plasma and low density lipoprotein exposed to oxidative stress in vitro. J Clin Invest. 1994;93(3):998–1004.PubMedCrossRef
38.
Morrow JD, Awad JA, Boss HJ, et al. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci U S A. 1992;89(22):10721–5.PubMedCrossRef
39.
Praticò D, Iuliano L, Mauriello A, et al. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J Clin Invest. 1997;100(8):2028–34.PubMedCrossRef
40.
Watson AD, Subbanagounder G, Welsbie DS, et al. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J Biol Chem. 1999;274(35):24787–98.PubMedCrossRef
41.
Birukov KG, Bochkov VN, Birukova AA, et al. Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac. Circ Res. 2004;95(9):892–901.PubMedCrossRef
42.
Poliakov E, Meer SG, Roy SC, et al. Iso[7]LGD2-protein adducts are abundant in vivo and free radical-induced oxidation of an arachidonyl phospholipid generates this D series isolevuglandin in vitro. Chem Res Toxicol. 2004;17(5):613–22.PubMedCrossRef
43.
Roberts 2nd LJ, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids. 2004;128(1–2):173–86.PubMedCrossRef
44.
Levy R. The role of cytosolic phospholipase a2-alfa in regulation of phagocytic functions. Biochim Biophys Acta. 2006;1761(11):1323–34.PubMedCrossRef
45.
Triggiani M, Granata F, Giannattasio G, Marone G. Secretory phospholipases a2 in inflammatory and allergic diseases: not just enzymes. J Allergy Clin Immunol. 2005;116(5):1000–6.PubMedCrossRef
46.
Dioszeghy V, Rosas M, Maskrey BH, et al. 12/15-Lipoxygenase regulates the inflammatory response to bacterial products in vivo. J Immunol. 2008;181(9):6514–24.PubMed
47.
Kondo M, Tamaoki J, Takeyama K, et al. Interleukin-13 induces goblet cell differentiation in primary cell culture from Guinea pig tracheal epithelium. Am J Respir Cell Mol Biol. 2002;27(5):536–41.PubMedCrossRef
48.
Kondo M, Tamaoki J, Takeyama K, et al. Elimination of IL-13 reverses established goblet cell metaplasia into ciliated epithelia in airway epithelial cell culture. Allergol Int. 2006;55(3):329–36.PubMedCrossRef
49.
50.
Brown CD, Kilty I, Yeadon M, Jenkinson S. Regulation of 15-lipoxygenase isozymes and mucin secretion by cytokines in cultured normal human bronchial epithelial cells. Inflamm Res. 2001;50(6):321–6.PubMedCrossRef
51.
Zhao J, Maskrey B, Balzar S, et al. Interleukin-13-induced MUC5AC is regulated by 15-lipoxygenase 1 pathway in human bronchial epithelial cells. Am J Respir Crit Care Med. 2009;179(9):782–90.PubMedCrossRef
52.
Zhao J, O'Donnell VB, Balzar S, et al. 15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MAPK signaling in humanairway epithelial cells. Proc Natl Acad Sci U S A. 2011;108(34):14246–51.PubMedCrossRef
53.
•• Uderhardt S, Herrmann M, Oskolkova OV, et al. 12/15-lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity. 2012;36(5):834–46. This elegant study shows the involvement of 12/15-lipoxygenase in the regulation of apoptotic cell clearance and maintenance of self-tolerance. PubMedCrossRef
54.
Maskrey BH, Bermúdez-Fajardo A, Morgan AH, et al. Activated platelets and monocytes generate four hydroxyphosphatidylethanolamines via lipoxygenase. J Biol Chem. 2007;282(28):20151–63.PubMedCrossRef
55.
Miller YI, Chang MK, Funk CD, et al. 12/15-lipoxygenase translocation enhances site-specific actin polymerization in macrophages phagocytosing apoptotic cells. J Biol Chem. 2001;276(22):19431–9.PubMedCrossRef
56.
von Schlieffen E, Oskolkova OV, Schabbauer G, et al. Multi-hit inhibition of circulating and cell-associated components of the toll-like receptor 4 pathway by oxidized phospholipids. Arterioscler Thromb Vasc Biol. 2009;29(3):356–62.CrossRef
57.
Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of ppar-gamma ligands in macrophages by 12/15-lipoxygenase. Nature. 1999;400:378–82.PubMedCrossRef
58.
Yeung J, Holinstat M. 12-lipoxygenase: a potential target for novel anti-platelet therapeutics. Cardiovasc Hematol Agents Med Chem. 2011;9(3):154–64.PubMedCrossRef
59.
Dogné JM, de Leval X, Delarge J, et al. New trends in thromboxane and prostacyclin modulators. Curr Med Chem. 2000;7(6):609–28.PubMedCrossRef
60.
Weinstein EA, Li H, Lawson JA, et al. Prothrombinase acceleration by oxidatively damaged phospholipids. J Biol Chem. 2000;275(30):22925–30.PubMedCrossRef
61.
Pickering W, Gray E, Goodall AH, Barrowcliffe TW. Effects of apoptosis and lipid peroxidation on T-lymphoblastoid phospholipid-dependent procoagulant activity. J Thromb Haemost. 2008;6(7):1122–30.PubMedCrossRef
62.
Kozak KR, Marnett LJ. Oxidative metabolism of endocannabinoids. Prostaglandins Leukot Essent Fat Acids. 2002;66(2–3):211–20.CrossRef
63.
Kozak KR, Crews BC, Morrow JD, et al. Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J Biol Chem. 2002;277(47):44877–85.PubMedCrossRef
64.
Rouzer CA, Marnett LJ. Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. J Biol Chem. 2005;280(29):26690–700.PubMedCrossRef
65.
66.
Döring Y, Drechsler M, Wantha S, et al. Lack of neutrophil-derived CRAMP reduces atherosclerosis in mice. Circ Res. 2012;110(8):1052–6.PubMedCrossRef
Metadata
Title
Oxidized PLs and Vascular Inflammation
Authors
Maceler Aldrovandi
Valerie B. O’Donnell
Publication date
01-05-2013
Publisher
Current Science Inc.
Published in
Current Atherosclerosis Reports / Issue 5/2013
Print ISSN: 1523-3804
Electronic ISSN: 1534-6242
DOI
https://doi.org/10.1007/s11883-013-0323-y

Other articles of this Issue 5/2013

Current Atherosclerosis Reports 5/2013 Go to the issue

Vascular Biology (RS Rosenson, Section Editor)

Modulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular Inflammation

Vascular Biology (RS Rosenson, Section Editor)

Polyphenols, Inflammation, and Cardiovascular Disease

Vascular Biology (RS Rosenson, Section Editor)

GPR109A and Vascular Inflammation

Genetics (AJ Marian, Section Editor)

MicroRNAs and Atherosclerosis

Vascular Biology (RS Rosenson, Section Editor)

Biomarkers and Sustainable Innovation in Cardiovascular Drug Development: Lessons from Near and Far Afield

Genetics (AJ Marian, Section Editor)

Epigenetic Regulation of Vascular Smooth Muscle Cell Function in Atherosclerosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits